Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1997 1
2000 1
2001 7
2002 7
2003 10
2004 6
2005 8
2006 16
2007 8
2008 12
2009 10
2010 15
2011 17
2012 21
2013 20
2014 18
2015 19
2016 33
2017 34
2018 34
2019 49
2020 35
2021 50
2022 50
2023 33
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Results by year

Filters applied: . Clear all
Page 1
Atopic Dermatitis.
Ständer S. Ständer S. N Engl J Med. 2021 Mar 25;384(12):1136-1143. doi: 10.1056/NEJMra2023911. N Engl J Med. 2021. PMID: 33761208 Review. No abstract available.
Pruritus in Pregnancy.
Stefaniak AA, Pereira MP, Zeidler C, Ständer S. Stefaniak AA, et al. Among authors: stander s. Am J Clin Dermatol. 2022 Mar;23(2):231-246. doi: 10.1007/s40257-021-00668-7. Epub 2022 Feb 21. Am J Clin Dermatol. 2022. PMID: 35191007 Free PMC article. Review.
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.
Kolkhir P, Akdis CA, Akdis M, Bachert C, Bieber T, Canonica GW, Guttman-Yassky E, Metz M, Mullol J, Palomares O, Renz H, Ständer S, Zuberbier T, Maurer M. Kolkhir P, et al. Among authors: stander s. Nat Rev Drug Discov. 2023 Sep;22(9):743-767. doi: 10.1038/s41573-023-00750-1. Epub 2023 Aug 1. Nat Rev Drug Discov. 2023. PMID: 37528191 Review.
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Staudinger HW, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT. Yosipovitch G, et al. Among authors: stander s. Nat Med. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4. Nat Med. 2023. PMID: 37142763 Free PMC article. Clinical Trial.
European S2k Guideline on Chronic Pruritus.
Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Giménez-Arnau AM, Lambert J, Leslie T, Mettang T, Misery L, Şavk E, Streit M, Tschachler E, Wallengren J, Ständer S. Weisshaar E, et al. Among authors: stander s. Acta Derm Venereol. 2019 Apr 1;99(5):469-506. doi: 10.2340/00015555-3164. Acta Derm Venereol. 2019. PMID: 30931482 Free article.
Diagnostic and treatment algorithm for chronic nodular prurigo.
Ständer HF, Elmariah S, Zeidler C, Spellman M, Ständer S. Ständer HF, et al. Among authors: stander s. J Am Acad Dermatol. 2020 Feb;82(2):460-468. doi: 10.1016/j.jaad.2019.07.022. Epub 2019 Jul 13. J Am Acad Dermatol. 2020. PMID: 31310842 Review.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: stander s. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.
Ujiie H, Rosmarin D, Schön MP, Ständer S, Boch K, Metz M, Maurer M, Thaci D, Schmidt E, Cole C, Amber KT, Didona D, Hertl M, Recke A, Graßhoff H, Hackel A, Schumann A, Riemekasten G, Bieber K, Sprow G, Dan J, Zillikens D, Sezin T, Christiano AM, Wolk K, Sabat R, Kridin K, Werth VP, Ludwig RJ. Ujiie H, et al. Among authors: stander s. Front Med (Lausanne). 2022 Jun 9;9:875492. doi: 10.3389/fmed.2022.875492. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35755063 Free PMC article. Review.
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J, Bieber T, Misery L, Wollenberg A, Reich A, Ahmad F, Piketty C. Ständer S, et al. N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316. N Engl J Med. 2020. PMID: 32074418 Clinical Trial.
478 results